PARP inhibitor maintenance therapy (mPARPi) is a common treatment for patients with newly diagnosed advanced ovarian cancer following surgery and platinum chemotherapy. Clinical trials have shown that mPARPi can benefit patients with and without BRCA1/2 mutations. However, it is unclear how effective mPARPi is for patients who do not have specific biomarkers without homologous recombination deficiency (HRD). Using the Flatiron Health-Foundation Medicine Clinico-Genomic Database, this study aimed to compare the effectiveness of mPARPi in real-world practice based on two biomarkers: BRCA1/2 mutation and/or a novel biomarker called HRD signature (HRDsig).
Why this matters
By comparing the outcomes of ovarian cancer patients with and without BRCA1/2 mutations and HRDsig, this study aims to determine the effectiveness of mPARPi in real-world clinical practice. This information can help clinicians better understand which patients are most likely to benefit from this treatment and make more informed decisions about treatment options.